Results 81 to 90 of about 86,105 (313)

Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of Rhodococcus equi from Foals in Central Kentucky, 1995 to 2017

Antimicrobial Agents and Chemotherapy, 2018
The objective of this study was to determine the prevalence of Rhodococcus equi strains resistant to macrolides and rifampin over time in clinical samples from foals submitted to diagnostic laboratories in central Kentucky.
L. Huber, S. Giguère, N. Slovis, C. Carter, B. Barr, N. Cohen, J. Elam, E. Erol, Stephan J. Locke, Erica Phillips, Jacqueline L. Smith   +10 more
semanticscholar   +1 more source

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

The Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller, Lauren Lohmer, Felix Beck, Jeegar Patel, Jasminder Sahi   +4 more
wiley   +1 more source

Identification of rifampin-regulated functional modules and related microRNAs in human hepatocytes based on the protein interaction network [PDF]

, 2016
BACKGROUND: In combination with gene expression profiles, the protein interaction network (PIN) constructs a dynamic network that includes multiple functional modules.
Cong, Wang, Dai, Xuefeng, Deng, Yulin, Feng, Weixing, Li, Jin, Liang, Hong, Liu, Yunlong, Skaar, Todd C., Wang, Lei, Wang, Ying, Wang, Yue, Xu, Chengzhen   +11 more
core   +1 more source

Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib

The Journal of Clinical Pharmacology, EarlyView.
Abstract Fruquintinib (FRUZAQLATM) is a highly selective tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3). Two Phase 1, open‐label, single‐dose studies investigated the impact of hepatic or renal impairment on the pharmacokinetics and tolerability of fruquintinib.
Martha Gonzalez, Zhao Yang, William Schelman, Thomas C. Marbury, Juan C. Rondon, William Smith, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +8 more
wiley   +1 more source

Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis

BMC Nephrology, 2013
Background Rifampin is one of the most important drugs in first-line therapies for tuberculosis. The renal toxicity of rifampin has been reported sporadically and acute tubulointerstitial nephritis (ATIN) is a frequent histological finding.
Min Hong Ki, Kim Eun Oh, Lee Sang Ju, Chang Yoon Kyung, Suh Kwang Sun, Yang Chul Woo, Kim Suk Young, Hwang Hyeon Seok   +7 more
doaj   +1 more source

Biofilm Time-Kill Curves to Assess the Bactericidal Activity of Daptomycin Combinations against Biofilm-Producing Vancomycin-Resistant Enterococcus faecium and faecalis

Antibiotics, 2021
Introduction: E. faecium and E. faecalis are responsible for 13.9% of hospital-acquired infections with frequent resistance to vancomycin (82.6% of E. faecium, 9.5% of E. faecalis).
Katie E. Barber, Zade Shammout, Jordan R. Smith, Razieh Kebriaei, Taylor Morrisette, Michael J. Rybak   +5 more
doaj   +1 more source

Mutations in 1700 Bp Fragment of Rpob Gene of Multi-drug Resistant Mycobacterium Tuberculosis Isolate [PDF]

, 2012
This research aimed to amplify a 1700 bp fragment of rpoB gene of multidrug resistance M. tuberculosis (MDR-TB) isolate and determine types of mutation beyond the core region (hot-spot region).
Junitha, I. K. (I), Mantik-Astawa, I. N. (I), Sukardika, I. K. (I), Yowani, C. (Chandra)   +3 more
core  

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

The Journal of Clinical Pharmacology, EarlyView.
Abstract Fruquintinib is a highly selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved by the US Food and Drug Administration and the European Commission for the treatment of previously treated metastatic colorectal cancer (mCRC), regardless of biomarker status. This study used concentration QT interval (C‐QTc)
Xiaofei Zhou, Alice Toms, Dave Morton, Xiaohui Wang, Adekemi Taylor, Arvind Dasari, Neeraj Gupta, Caly Chien   +7 more
wiley   +1 more source

Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series

Biomedicines, 2023
Vaccination with Bacillus Calmette–Guérin (BCG) can be harmful to patients with combined primary immunodeficiencies. We report the outcome of BCG vaccination in a series of twelve patients affected by adenosine deaminase deficiency (ADA-SCID).
Daniele Canarutto, Chiara Oltolini, Federica Barzaghi, Valeria Calbi, Maddalena Migliavacca, Francesca Tucci, Vera Gallo, Giulia Consiglieri, Francesca Ferrua, Salvatore Recupero, Maria Celia Cervi, Hamoud Al-Mousa, Anna Pituch-Noworolska, Chiara Tassan Din, Paolo Scarpellini, Paolo Silvani, Claudia Fossati, Miriam Casiraghi, Daniela Maria Cirillo, Antonella Castagna, Maria Ester Bernardo, Alessandro Aiuti, Maria Pia Cicalese   +22 more
doaj   +1 more source

Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant Acinetobacter baumannii causing ventilator-associated pneumonia [PDF]

, 2017
We present the case of a patient with ventilator-associated pneumonia (VAP) caused by a pan-resistant Acinetobacter baumannii successfully treated with the combination colistin plus vancomycin plus rifampin, whose in vitro activity was investigated by ...
Cipolla, Alessia, Falcone, Marco, Mastroianni, Claudio Maria, Oliva, Alessandra, Venditti, Mario, Vullo, Vincenzo   +5 more
core   +1 more source